Illumina has appointed Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, bringing extensive experience in drug discovery, clinical development, and translational medicine. Illumina CEO Jacob Thaysen said his expertise in building and advancing large research portfolios will help strengthen the company's innovation across genomics, multiomics, and precision medicine. Dr. Skovronsky joined Lilly in 2010 after the acquisition of Avid Radiopharmaceuticals, a company he founded and led as CEO, and previously served on the board of Myriad Genetics.
Illumina IncAppointment of Eli Lilly's CSO with deep drug discovery and translational medicine expertise to strengthen Illumina's innovation in genomics and precision medicine.
Eli Lilly and Company
Myriad Genetics Inc